Gastrointestinal Emergencies and the Role of Endoscopy

Vinod Kumar Dixit1  Manoj Kumar Sahu2  Vybhav Venkatesh2  Varanasi Yugandhar Bhargav3
Vinod Kumar1  Mayank Bhushan Pateriya1  Jayanthi Venkataraman3

1 Department of Gastroenterology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India
2 Department of Gastroenterology and Hepatobiliary Sciences, Institute of Medical Sciences and SUM Hospital, Siksha ‘O’ Anusandhan (SOA) University, Bhubaneswar, Odisha, India
3 Department of Hepatology, Sri Ramachandra Institute of Higher Education and Research, Chennai, Tamil Nadu, India


Address for correspondence Manoj Kumar Sahu, MD, DM, Department of Gastroenterology and Hepatobiliary Sciences, Institute of Medical Science and SUM Hospital, SOA University, Bhubaneswar, Odisha, India (e-mail: manojsahu427@gmail.com).

Abstract

Many gastrointestinal (GI) disorders present to the emergency room with acute clinical presentations, some even life threatening. Common emergencies encountered that require urgent endoscopic interventions include GI hemorrhage (variceal and nonvariceal), foreign body ingestion, obstructive jaundice, postprocedure-related complications such as postpolypectomy bleed or perforation, etc. A major advantage of emergency endoscopy is that it is cost effective and, on many occasions, can be life-saving. The present review will highlight a practical approach on various endoscopic modalities and their use in the GI emergencies.

Keywords
► endoscopy
► gastrointestinal hemorrhage
► foreign body
► obstructive jaundice

Acute Gastrointestinal Bleed

Acute upper gastrointestinal bleeding (UGIB) is a common medical emergency. In a fraction of the patients, the bleeding stops spontaneously.1–3 However, in a subset, the bleed persists or recurs after initial control. These high-risk patients have significant mortality rates which can be reduced by the emergency endoscopic interventions. The cost effectiveness of the endoscopy and its related interventions have been shown by few researchers.4,5

There are several prognostic indices for UGIB that help the clinician for the purpose of patient stratification and management. While the popular Rockall score incorporates clinical parameters and endoscopy findings to predict mortality, the Glasgow-Blatchford score (GBS) is a pre-endoscopy score that predicts the need for any blood transfusion, endoscopy, or surgery. The Rockall score includes five components—age, shock, comorbidities, source of bleed, and stigmata of recent hemorrhage (SRH); while the GBS includes hemoglobin, blood urea nitrogen, systolic blood pressure, pulse rate, and presence or absence of comorbidities. The AIMS65 (albumin, international normalized ratio [INR], mental state, systolic blood pressure) score predicts the timing for endoscopy and mortality.6 An international multicenter study involving 3,012 patients with UGIB compared the performance three pre-endoscopic scores to predict various outcomes.7 In this study, a GBS ≤ 1 was best for directing patients to outpatient management and had a sensitivity of 98.6% with specificity of 34.6% for predicting survival without intervention. With a sensitivity of 80% and specificity of 57%, a GBS ≥ 7 was best to predict the need for endoscopic treatment. AIMS65 score of ≥ 2 and clinical...
Rockall score of ≥ 4 were optimal at predicting death, with sensitivities of 65.8 to 78.6% and specificities of 65.0 to 65.3%. The 10-point Progetto Nazionale Emorragia Digestiva (PNED) score proposed by the Italian group was found to have high discriminant capability and superior to Rockall score in predicting mortality in patients with nonvariceal UGIB, with PNED score ≥ 8 having a positive likelihood ratio for mortality of 16.05. The most recent one is the ABC (age, blood test, comorbidity) score to predict the 30-day mortality of patients with upper or lower GI bleed (LGB; area under the receiver operating characteristic 0.81–0.84). A score of ≤ 3 was considered low risk, 4 to 7 as medium risk, and ≥ 8 as high-risk. Studies on the utility of these scores in Indian patients are limited. In a study among 300 patients with UGIB, 55.3% with variceal bleed by Chandnani et al., Rockall score was superior to others in predicting mortality (score ≥ 3 had sensitivity of 90% and specificity of 35%), while the PNED (score ≥ 1 had sensitivity of 91% and specificity of 22%) was better for predicting rebleeding, and GBS was better for predicting need for blood transfusions or interventions (score of 2 had 98% sensitivity, 20% specificity for transfusion need; and score of 3 had 97% sensitivity with 31% specificity for predicting the need of interventions). Other Indian studies showed that these scoring systems perform well in patients with nonvariceal UGIB.

**General Considerations in the Management**

Initial immediate assessment of hemodynamic status is of utmost importance followed by the prompt intravascular volume replacement. Placement of a nasogastric tube has limited diagnostic and prognostic value. Restrictive red blood cell transfusion strategy aims for a target hemoglobin between 7 and 9 g/dL. A randomized control trial (RCT) involving 921 patients with acute UGIB compared this restrictive versus liberal transfusion strategies and concluded that those in the restrictive group had less rebleeding rates (10% vs. 16%; hazard ratio [HR] 0.68, 95% confidence interval [CI]: 0.47–0.98) and better 6-week survival (95% vs. 91%; HR 0.55; 95% CI: 0.33–0.92). Liberal red blood cell transfusion strategy (target hemoglobin of 9–11 g/dL or more) was reported to have poor outcomes in few studies. A recent meta-analysis which included 1,965 participants reported that restrictive transfusion was associated with lower risk of all-cause mortality and rebleeding. Most of the guidelines also recommend the use of restrictive transfusion strategy and imply that a higher threshold for transfusion should be considered in patients with comorbidities like ischemic heart disease. The data regarding this specific patient population is limited. A single RCT provided the subgroup analysis data on UGIB patients with and without cardiovascular disease which concluded that there was no difference between restrictive (hemoglobin threshold 8 g/dL) versus liberal transfusion (hemoglobin threshold 10 g/dL) with regards to mortality and rebleeding. A recent international consensus guidelines recommend a higher threshold for transfusion (< 8 g/dL) in UGIB patients with cardiovascular disease. Endotracheal intubation is recommended in those requiring an upper GI endoscopy (UGIE) for ongoing active hemorrhage, those agitated, or in a state of hepatic encephalopathy. Patients who are on antithrombotic therapy (antiplatelet/anticoagulants) should be carefully assessed and the risk–benefit ratio should be taken into account regarding the decisions on continuation of therapy. The European Society for Gastrointestinal Endoscopy (ESGE) guidelines recommend to withhold aspirin temporarily and restart after 5 days if it was given for primary cardiovascular prophylaxis. If aspirin was started as monotherapy or in combination for secondary cardiovascular prevention, many guidelines recommend to continue its usage. It is recommended that endoscopy should not be delayed in patients on anticoagulants, and coagulopathy should be corrected. In a study by Nagata et al, anticoagulant interruption did not affect risks and early endoscopy was found to be safe. The recommendation from the ESGE guidelines state that all the anticoagulants need to be stopped temporarily and can be resumed within 1 week of hemostasis and can be bridged with heparin in patients with high risk of thromboembolism. Reversal of anticoagulation using vitamin K, prothrombin complex concentrates, or fresh frozen plasma and reversal agents for direct oral anticoagulants should be considered in case of hemodynamic instability.

**Upper GI Bleed**

UGIB can be variceal or nonvariceal. This can be a life-threatening emergency carrying the risk of rebleed and mortality despite standard pharmacological and endoscopic management. In contrast to literature from northern and western India where variceal bleed is the most common cause of UGIB, latest studies from eastern and southern India have shown peptic ulcer disease to be the leading cause of UGIB followed by variceal bleed, esophagogastric malignancy, erosive gastroduodenitis, and others. The overall rebleed rates are high in the first 6 weeks.

**Urgent versus Early Endoscopy**

UGIE within 24 hours is referred to as early endoscopy (urgent, within 6 hours) and that performed beyond 24 hours is termed delayed/elective endoscopy. The GBS is suitable to triage patients for an urgent endoscopy. Those with higher score require early endotherapy and those with low GBS can be managed as outpatients. In a recent randomized trial among patients with acute UGIB at high risk for further bleeding or death (GBS ≥ 12), no difference in 30-day mortality was observed between urgent (within 6 hours) and early (within 6–24 hours) endoscopy groups (mortality rate 8.9% vs. 6.6%, p = 0.34).

**Nonvariceal Bleed**

**Gastric/Duodenal Ulcer**

Patients should be initiated on high-dose intravenous proton-pump inhibitors, while awaiting UGIE. Intravenous metoclopramide or erythromycin (single dose, 250 mg given 30–120 minutes prior to UGIE) in those with severe or ongoing, active UGIB improves endoscopic visualization.
Forrest (F) classification is used in patients with peptic ulcer hemorrhage; management is based on the type of bleeding ulcer.\textsuperscript{19} F1a or F1b ulcers are independent risk factors for persistent bleed or rebleed. In addition, large-size ulcer (> 2 cm), large-size nonbleeding visible vessel, presence of blood in the gastric lumen, and ulcer location on the posterior duodenal wall or the proximal lesser curvature of the stomach are other endoscopic features that predict adverse outcomes and/or endoscopic treatment failure.\textsuperscript{30–32}

Management: For F1a and F1b ulcers, epinephrine injection is combined with a second hemostatic modality like contact thermal, mechanical therapy, or injecting a sclerosant. A Cochrane review concluded that combination of a second modality with epinephrine injection is superior to epinephrine monotherapy alone to reduce the risk of rebleeding (relative risk [RR] 0.53; 95% CI: 0.35–0.81) and the need for emergency surgery (RR 0.57, 95% CI: 0.43–0.76).\textsuperscript{33} This review included 12 studies which compared epinephrine versus epinephrine plus second injected agent (like thrombin, fibrin glue, ethanolamine, ethanol, sodium tetradecyl sulfate, and polidocanol), 3 studies which compared epinephrine versus epinephrine plus thermal therapy (heat probe, bipolar electrocautery, and laser photococagulation) and 4 studies that compared epinephrine versus epinephrine plus mechanical methods (band ligation and hemoclips). Through the scope (OTS) caps were specifically developed for use in endoscopic hemostasis of GI tract lesions and have been in use for many years. A meta-analyses by Baracat et al\textsuperscript{34} looked at various RCTs which studied hemoclips versus other therapies for endoscopic hemostasis of peptic ulcer bleeding and concluded that hemoclip was superior to injection therapy in terms of rebleeding. Although TTS caps are relatively easy to use, clipping of large defects and access to the proper position are difficult at times. The cap-mounted clips or over the scope (OTS) clip (OSTC) are rescue/salvage options for uncontrolled bleed which were initially developed for endoscopic closure of GI perforations and fistulae. Compared with TTS caps, cap-mounted clips are able to compress a larger amount of tissue and hence can offer better hemostasis. Many prospective studies evaluated the role of OTSC as a primary hemostatic modality in nonvariceal UGIB with promising results and it was found to be useful in those with comorbidities like cardiovascular diseases or undergoing antithrombotic therapy.\textsuperscript{35–39} A multicenter RCT (STING trial) comparing OTSC versus standard endoscopic therapy with TTS concluded that OTSC was superior to TTS clips in patients with recurrent peptic ulcer bleeds.\textsuperscript{40} OTSC is usually recommended in ulcers > 2 cm, ulcers with a large visible vessel > 2 mm, or ulcers located in high-risk vascular area (gastroduodenal and gastric arteries). The hemospray is an inorganic mineral powder that binds to sites which are actively bleeding to achieve hemostasis and is washed away within 12 to 24 hours. It is found to be useful and cost effective in managing nonvariceal UGIB.\textsuperscript{41} A systematic review of observational data found an immediate hemostasis rate of 90% but high rebleeding rates after therapy with hemospray. Another recent meta-analysis by Mutneja et al\textsuperscript{42} included 11 prospective studies and found that the pooled immediate hemostasis rate was 93% and rebleeding rate was 14.4% with hemospray. If there is failure to control bleed by any of the methods hitherto mentioned, one may have to resort to transcatheter vascular embolization or even surgery. The endoscopic methods of hemostasis are summarized in Table 1 and the Forrest classification-based management with rebleed rates is summarized in Table 2.\textsuperscript{20,43}

**Dieulafoy’s Lesion**

It is an uncommon cause of obscure UGIB (1–2%) which can be life threatening.\textsuperscript{44} The most common site (80–95%) is along the lesser curve of the stomach within 6 cm of the gastroesophageal junction. The high prevalence along lesser curve is related to the vessel arising directly from the artery and not from the submucosal plexus that are seen in the rest of the stomach. The persistent artery has a width of 1 to 3 mm and has a tortuous course within the submucosa. The lesion protrudes through a small mucosal defect that is approximately 2 to 5 mm. A typical patient is an elderly male with multiple comorbidities, on drugs like warfarin and aspirin presenting with massive and/or recurrent GI bleed. The first line of evaluation is performing an UGIE. Occasionally, repeat endoscopy may be indicated in 16 to 20%.\textsuperscript{15} For lesions beyond the stomach, enteroscopy, wireless capsule endoscopy (therapeutic intervention not possible), or a per-operative enteroscopy are the alternatives. Findings at endoscopy include a protruding vessel surrounded by normal mucosa, no associated ulcer, spurring or oozing of blood from the pin point defect (<3 mm), or a clot without an ulcer. Endoscopic methods of hemostasis include combination of any of the two following modalities: thermal coagulation: electrocoagulation, heat probe coagulation, and argon plasma coagulation (APC); local injection: epinephrine or sclerotherapy; and mechanical: banding or placement of a hemoclip. Endoscopic hemostasis is effective in more than 90% instances and significantly reduces the mortality rate. Endoscopic ultrasound (EUS)-guided procedure ablates the aberrant vessel under direct vision and absence of blood flow confirms the success of the procedure.\textsuperscript{45} Tattooing of the lesion is important in case of rebleeding and if surgery is contemplated.

**Mallory-Weiss Tear**

Repeated retching can cause a significant bleed and at times will require an emergency endoscopy. The bleed is best managed by mechanical therapy or thermal coagulation. The commonly used endoscopic methods for control of bleeding in Mallory-Weiss tear are injection therapy, APC, hemoclip placement, and band ligation.\textsuperscript{46} Miscellaneous causes of bleed due to vascular ectasia, esophago-gastroduodenitis, or due to malignancy seldom requires an emergency intervention.

**Post-Sphincterotomy Bleed**

Complications following endoscopic sphincterotomy (ES) during endoscopic retrograde cholangiopancreatography (ERCP) include pancreatitis, bleeding, perforation, cholangitis, and adverse cardiopulmonary events with incidence
rates varying from 0.1 to 2%.\textsuperscript{47} Post-ES bleed can be immediate (during the procedure) or delayed (postprocedure few hours to several days), and insignificant or life threatening. Immediate bleeding is more frequent than delayed bleeding. Risk factors for post-ES bleeding include coagulopathy, anticoagulation within 3 days of ES, cholangitis before ERCP, and bleeding during initial ES. Bleed rates are high in cirrhosis, periampullary diverticulum, precut sphincterotomy, and large bile duct stones.\textsuperscript{48} Most bleeding episodes are managed successfully by prompt and appropriate resuscitative measures and management of comorbid conditions without the need for endotherapy. Preventive methods to reduce post-ES bleed include use of newer electrosurgical generators that incorporate feedback control (endo-cut), and prevents zipper cutting, performing balloon sphincteroplasty in patients with coagulopathy, maintaining a platelet count of $>50,000$ cells/mm$^3$ and an INR $\leq 1.5$ in cirrhotic patients, and use of fresh frozen plasma in those on anticoagulants.

The options for endoscopic hemostasis mirror those techniques adopted for peptic ulcer bleed and include injection, thermal, and mechanical methods (endoclips), either alone or in combination. Thermal coaptive coagulation can be performed using bipolar or heater probe devices.\textsuperscript{47,49}

### Table 1

**Modalities of endoscopic hemostasis: mechanism and indications for use**

<table>
<thead>
<tr>
<th>Serial no.</th>
<th>Modality</th>
<th>Specifics</th>
<th>Mechanism of action</th>
<th>Indications for use</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Diluted epinephrine</td>
<td>1:10 000 or 1:20 000 with normal saline injected in 0.5–2-mL aliquots in and around the ulcer base</td>
<td>It has a local tamponade effect and produces local vasoconstriction</td>
<td>Gastric/duodenal ulcers, Mallory-Dieulafoy lesion, post-sphincterotomy bleed, diverticular bleeding, post-polypectomy bleeds</td>
</tr>
<tr>
<td>2.</td>
<td>Sclerosing agents</td>
<td>Absolute ethanol, ethanolamine, polidocanol</td>
<td>Produce hemostasis by causing direct tissue injury and thrombosis. The volume injected should be small because of concerns on tissue necrosis, perforation, pancreatitis</td>
<td>Gastric/duodenal ulcers, variceal bleeds</td>
</tr>
<tr>
<td>3.</td>
<td>Tissue adhesives</td>
<td>Thrombin, fibrin, cyanoacrylate glues</td>
<td>Endoscopic injection of these agents creates a primary seal at the site of bleed</td>
<td>Gastric/duodenal ulcers, variceal bleeds</td>
</tr>
<tr>
<td>4.</td>
<td>Thermal therapy</td>
<td>Contact: heater probes and bipolar electrocautery probes Noncontact: argon plasma coagulation (APC)</td>
<td>Heat generated from these devices leads to edema, coagulation of tissue proteins, contraction of vessels, and indirect activation of the coagulation cascade, resulting in a hemostatic bond</td>
<td>Gastric/duodenal ulcers, Mallory-Dieulafoy’s lesion, tumor bleeds, gastric antral vascular ectasia (GAVE), angiectasia, radiation proctitis</td>
</tr>
<tr>
<td>5.</td>
<td>Mechanical therapy</td>
<td>Through-the-scope (TTS) and over-the-scope (OTS) clips, band ligation devices</td>
<td>Endoscopic clips are deployed directly onto a bleeding site and typically slough off within days to weeks after placement. Hemostasis is achieved by mechanical compression of the bleeding site</td>
<td>Gastric/duodenal ulcers, Mallory-Weiss tear, Mallory-Dieulafoy’s lesion, diverticular bleeding, postpolypectomy bleeds</td>
</tr>
<tr>
<td>6.</td>
<td>Topical therapy</td>
<td>TC-325 (Hemospray)</td>
<td>Inorganic, absorbent powder that rapidly concentrates clotting factors at the bleeding site, forming a coagulum</td>
<td>Gastric/duodenal ulcers, tumor bleeds, post-endoscopic variceal ligation (EVL) ulcers, post-sphincterotomy bleeds</td>
</tr>
</tbody>
</table>

### Table 2

**Endoscopic modalities according to Forrest classification**

<table>
<thead>
<tr>
<th>Stage</th>
<th>Rebleed without therapy</th>
<th>Endoscopic hemostasis technique</th>
<th>Initial hemostasis</th>
<th>Rebleed after therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ia- Spurting</td>
<td>20–95%</td>
<td>Epinephrine injection + second modality (thermal/ mechanical therapy)</td>
<td>90–100%</td>
<td>0–30%</td>
</tr>
<tr>
<td>Ib- Oozing</td>
<td></td>
<td>Thermal/ mechanical therapy, or injection of a sclerosing agent, each as monotherapy or in combination with epinephrine injection</td>
<td>90–100%</td>
<td>5–30%</td>
</tr>
<tr>
<td>IIa- Nonbleeding visible vessel</td>
<td>30–50%</td>
<td>Controversial: Clot removal followed by endoscopic hemostasis or medical management</td>
<td>90–100%</td>
<td>5–20%</td>
</tr>
<tr>
<td>IIb- Adherent clot</td>
<td>25–50%</td>
<td>Low risk No endoscopic hemostasis required</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IIc- Flat/pigmented spot</td>
<td>3–10%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>III- Clean base ulcer</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Injection of dilute epinephrine into and around the sphincterotomy site is the simplest and ideal. Caution must be exerted in patients with underlying coronary artery disease or cardiac arrhythmias. There are limited data on the use of clips for post-ES hemostasis. Balloon tamponade is a commonly employed modality to control post-ES bleed. The use of self-expanding metal stents to control refractory bleeds has provided another tool in the armamentarium. With the availability of various endoscopic modalities of intervention, the mortality rate of post-ES bleeding, is currently < 0.1%.

**Hemobilia**

This refers to extravasated gross blood in the biliary system from venous or arterial source and is an important cause of massive UGIB, requiring an emergency intervention. It is an important differential for obscure GI bleed. Common causes are iatrogenic, trauma, gallbladder and bile duct stones, and biliary neoplasia. The classic presentation of hemobilia is jaundice, right upper quadrant abdominal pain, and UGIB. Post-ERCP hemobilia presents either immediately or within a few days after the inciting duct injury (e.g., sphincterotomy or stricturoplasty). Primary endoscopic interventions aim at achieving hemostasis and maintaining bile flow. Patients presenting with minor hemobilia are managed conservatively with intravenous fluids and correction of coagulopathy. Major hemobilia requires hemodynamic stabilization and institution of urgent advanced endoscopic, interventional radiologic, or surgical intervention. UGIE with direct visualization of blood or clot emerging from the biliary tract confirms the diagnosis. ERCP offers therapeutic intervention, especially removal of the blood clots that appear as amorphous, tubular, or cast-like filling defects within the bile duct. Blood clots within the biliary tree predispose to obstructive jaundice, cholangitis, cholecystitis, and pancreatitis. EUS is complementary and assists in evaluation of vascular aneurysms, portal biliopancreatic-related bleed in addition to identifying blood clots in the biliary tree when ERCP findings are equivocal.

Endoscopic techniques to achieve hemostasis depend on the site of bleed. For bleed at the level of ampulla (e.g., post-sphincterotomy hemobilia), treatment options include spraying diluted epinephrine over the area of hemorrhage, or any of the hemostatic modalities already mentioned. Bleed occurring proximally (e.g., perihilar bleed), requires extraction of intraductal clots using extraction balloon catheters and retrieval baskets followed by stent deployment. Stents, especially fully covered self-expanding metallic stents (SEMS) achieve a tamponade effect, maintain luminal patency and bile flow, and serve as a salvage therapy to interventional radiology or surgery.

**Variceal Bleed**

**Esophageal Variceal Bleed**

This is a major complication of portal hypertension with high morbidity and mortality. The risk of bleeding depends on the size, presence of red color signs (RCS), and the degree of liver dysfunction. Esophageal varices are classified as small (< 5 mm) and low-risk (without RCS) or large (> 5 mm) and high-risk (with RCS). The recent classification has reclassified fundal varices as lesser curve, cardio-fundal, and distal gastric varices. Bleeding within 5 days of presentation is considered as an acute variceal bleeding (AVB) episode and is due to a rise in hepatic venous pressure gradient (HVPG), an independent predictor of variceal bleed, which persists up to 5 days after endotherapy. Rebleed is defined as the bleeding after 5 days of the index episode.

**Management:** Maintenance of airway, breathing, circulation, and assessment of severity are very important for the management of AVB. Restrictive blood transfusion strategy is recommended for all UGIB including variceal bleed. Endoscopic management along with pharmacotherapy is the standard of care for managing AVB. Current recommendation is combining vasoactive drugs (terlipressin/octreotide/somatostatin) for 2 to 5 days, prophylactic antibiotics, and endoscopic procedures (<Fig. 1>). Early endoscopy is recommended for AVB within 12 hours, once resuscitation is adequate. Endoscopic variceal ligation (EVL) is the preferred modality (<Fig. 2A>), and endoscopic sclerotherapy is reserved when EVL is not technically feasible. HVPG has a good predictive value for rebleed after initial control and is ideal to guide further therapy. Salvage procedures include early transjugular intrahepatic portosystemic shunt (TIPS) in those with high risk of variceal bleed (HVPG > 20 or active bleeding during endoscopy). In desperate situations, Sengstaken-Blakemore tube can be used and kept for a maximum of 24 to 48 hours. Fully covered SEMS (Ella Danis) is increasingly being used with the same indication. Hemostatic powders have been used for post-EVL ulcers, currently are used as a bridging therapy until definitive endoscopy is possible. The only validated option when hemostasis is not available, is injection of cyanoacrylate beneath the ulcer base in conjunction with pharmacotherapy. TIPS is considered the definitive rescue for failure of endoscopic therapy to control variceal bleeding.

**Gastric Variceal Bleeding**

Gastric variceal bleeding (GVB) tends to be more severe, requires more transfusions, and is associated with higher mortality. The current management strategies include pharmacotherapy, endotherapy, TIPS, balloon-occluded retrograde transvenous obliteration (BRTO), and surgical intervention. Endoscopic therapy mainly consists of cyanoacrylate injection to achieve hemostasis. When this fails, TIPS or BRTO may be considered. Both are safe and effective interventional treatments in the management of GVB. EUS-guided coiling with or without cyanoacrylate injection may also be useful, but needs more evidence.

**Lower GI Bleed**

LGIB accounts for 20 to 30% of cases of GI bleed, and in majority, the bleed stops spontaneously. While diverticular bleeding is the most common cause of LGIB in Western countries, colorectal polyps/malignancies and colitis are the
common causes in tropical countries. The general principles of initial management and resuscitation apply for LGIB as well. In contrast to UGIB, the risk stratification scores are not well validated in patients with LGIB. Patients with a shock index (heart rate/systolic blood pressure) of >1 are classified as having unstable LGIB as per the British guidelines and the index also predicts extravasation of contrast on angiography in patients with LGIB and can identify patients with active bleed. A recently proposed and validated Oakland score includes variables like age, gender, previous hospital admission with LGIB, blood on digital rectal examination, heart rate, systolic blood pressure, and hemoglobin. A cutoff of 8 points in Oakland score can help in triaging patients with LGIB (≤8, minor bleed–can be discharged, >8, major bleed–requires hospitalization and evaluation). Few guidelines recommend that those with high-risk clinical features (such as hemodynamic instability at presentation, comorbid illnesses, age >60 years, a history of diverticulosis or angiectasia, elevated creatinine) and signs of ongoing bleed should undergo early colonoscopy. Nevertheless, the need for urgent colonoscopic evaluation should be decided on case-to-case basis. The optimal timing of colonoscopy remains controversial. The results from recent RCTs and meta-analyses show that though that early colonoscopy (within 24 hours) improves the identification of the bleeding source, there is no clear evidence that it reduces important rebleeding rates or mortality compared with elective colonoscopy (after 24 hours).

Colonic Diverticular Bleed
Colonic diverticular bleeding is the most common cause of overt LGIB in adults. In most cases, the bleed stops spontaneously. However, if the bleeding persists, endoscopic intervention may be required. Hematochezia due to colonic diverticulosis is often an acute-onset painless bleed. Evaluation includes a detailed history and physical examination,
details of medication, comorbid states (chronic kidney disease, cirrhosis, hypertension, diabetes), and baseline laboratory tests. Rebleed rates and risk of thromboembolism are high in those on antiplatelet or anticoagulants.

All patients with acute LGIB due to colonic diverticular disease who either have continuous or rebleed after admission need to be triaged to either endotherapy, arterial embolization, or colectomy. Bowel preparation with oral lavage is recommended before the colonoscopic procedure. Cecal intubation is low in those with an unprepared colon. Most diverticula bleed either from the base or neck of the diverticulum due to damage to the vasa recta. Right-sided visualization of the colon is important as most lesions that bleed are from the wide-mouthed diverticulum. Colonoscopy evidence of active bleed or stigmata of recent hemorrhage (nonbleeding vessels, underlying adherent clot, and their combinations) require endoscopic hemostasis. Rebleed rates are high if hemostasis is not achieved by endoscopic or radiological maneuvers. The yield of picking up SRH improves by doing colonoscopy within 24 hours, ensuring adequate preparation with oral colonic lavage and using endoscopic water jet attached to the scope. Endoscopic hemostasis is the first-line treatment for colonic diverticular bleeding and the methods include epinephrine injection, coagulation, clipping, and ligation (endoscopic band ligation and detachable snare ligation) and more recently the use of OTS system. Epinephrine injection is indicated when the opening is small and the base is large and eversion of the diverticulum is difficult. Epinephrine on its own increases rebleed rate and hence given as a combination with other tamponade procedures like ligation. Coagulation current is not recommended when bleeding occurs from the base of the diverticulum. Clipping can be either closure of the mouth of diverticula or direct clipping of the vasa recta. It is indicated when the diverticulum opening is wide. Alternative to clipping is achieving mechanical ligation by either direct endoscopic band ligation or use of a detachable snare ligation and these are also indicated for rebleeds. Anticoagulant and platelet therapy that has been discontinued temporarily is to be resumed within 7 days; thereby reducing the risk of thromboembolism. It can be initiated when bleed is controlled. Arterial embolization is indicated when endoscopic methods fail, when bleed is massive, and failure to achieve hemostasis. Overall, while initial hemostasis and rebleed rates are similar between the hemostatic procedures, conversion to arterial embolization/surgery is least after ligation and highest in those after coagulation therapy. Perforation is common after ligation while clipping results in a high percentage of septicemia.

**Postpolypectomy Bleed**

Bleed following polypectomy occurs either immediately or several hours to weeks after the procedure due to either sloughing of the eschar or widening areas of necrosis due to thermal injury. The bleed can be significant due to an arterial spur or can present as a minor ooze. Depth of injury can occasionally extend even into the submucosal layer. The risk of delayed bleed is higher in those with polyps > 2 cm, polyps located in the right side of the colon, and on drugs (warfarin, aspirin, etc.). Significant bleed with hemodynamic instability requires hospitalization, prompt resuscitation with blood transfusion, correction of coagulopathies, and an urgent endoscopic intervention.

Emergency colonoscopy after a polyethylene glycol preparation is recommended in those with ongoing bleed. Most bleeds can be controlled endoscopically. The role of prophylactic clipping is debatable and should be individualized taking the risk factors into account. A multicenter RCT comparing the use of prophylactic clipping versus endoloop found no differences in bleeding rates. A recent multicenter retrospective analysis concluded that prophylactic endoloop application was high likely to inhibit immediate bleeding with polyp size > 15 mm. For immediate bleeds (occurring during or soon after the procedure), injection of diluted adrenaline and placement of a hemoclip is preferred. For postpolypectomy bleed (PPB) in a pedunculated polyp, the residual pedicle is grasped with a snare and pressure is applied for approximately 5 minutes (tamponade effect). Failure to control bleed necessitates submucosal injection of diluted adrenaline followed by hemoclip, that is applied directly over the bleeding site or of the residual stalk. In those with no stalk postpolypectomy or those with PPB from a sessile polyp, thermocoagulation (heater probe, tip of polypectomy snare) should be considered with or without injection of epinephrine. Other methods include APC and band ligation. Delayed PPB is managed on similar lines as early bleed with the use of hemoclips, thermocoagulation with or without the need for submucosal adrenaline injection, or a hemospray. The injected adrenaline often undergoes dilution due the inflammatory response following polypectomy and hence may not be effective in maintaining hemostasis. Hemospray can be used as monotherapy or in combination with other methods.

**Small Bowel Bleed**

Small bowel bleed (SBB) is relatively uncommon accounting for 5 to 10% of all GI bleeds and indicates that the source of bleeding is anatomically situated distal to ampulla of Vater till the proximal ileocecal valve. It can be occult (insidious), iron deficiency anemia ± positive fecal occult blood test) or overt (melena, hematemesis, hematochezia) and the causes include angiectasia/angiodyplasia, Dieulafoy’s lesion, inflammatory bowel disease, neoplasia, nonsteroidal anti-inflammatory drug-induced ulcers, polyposis syndromes, blue rubber bleb syndrome, among others. A detailed description of SBB is beyond the scope of this review and hence only salient points are discussed and a simplified approach is depicted in Fig. 3. Localization of SBB might be a tedious process but with the availability of different endoscopic modalities like double-balloon enteroscopy (DBE), single-balloon enteroscopy (SBE), video capsule endoscopy (VCE), and spiral enteroscopy (SE) the diagnosis could be achieved in most of the cases. A second-look endoscopy should be done as it is observed that 15 to 20% of patients have an upper or lower GI source of bleeding which could have been missed.
in the initial endoscopy evaluation. VCE allows noninvasive evaluation of the entire small bowel in 79 to 90% of patients, with a diagnostic yield of 38 to 83% in patients with suspected small bowel bleeding. It is very well tolerated by patients and the main complication is capsule retention in a fraction. A meta-analysis of 14 studies comparing the yield of VCE with push enteroscopy for evaluation of SBB reported higher diagnostic yield for VCE (63% vs. 28%, \( p < 0.01 \)) and it had a higher yield for detection of vascular and inflammatory lesions than tumors. Radiographic investigations commonly used in the evaluation of SBB include computed tomography (CT) enterography and CT angiography. CT enterography can be performed in patients with negative VCE because of higher sensitivity for the detection of mural-based small bowel masses and should also be considered prior to VCE in patients with suspected obstruction/stenosis (inflammatory bowel disease, prior radiotherapy, previous bowel surgery). In a meta-analysis of 18 studies, CT enterography had a pooled yield of 40% compared with 53% for VCE. CT angiography is usually performed to detect the site of active bleeding in cases of acute overt bleeding and was reported to detect bleeding rates as slow as 0.3 mL/min. In a meta-analysis of 9 studies with 198 patients showed CT angiography had a pooled sensitivity of 89% and specificity of 85% in diagnosing acute GI bleeding. The major limitation of CT angiography is that therapeutic intervention cannot be performed on identification of lesion which can be overcome using the newer endoscopic techniques. DBE, SBE, and SE are deep enteroscopy techniques which allow for the better visualization of small bowel that require an overtube for the scope advancement, and allow to perform therapeutic procedures at the same time. The diagnostic yield of these endoscopic techniques ranges from 60 to 80%. More recently, a novel motorized SE technique with a diagnostic yield of 66% for evaluation of small bowel disease was described by Ramchandani et al.

**Cholangitis**

The most common cause for cholangitis is choledocholithiasis. The prevalence of common bile duct stones (CBDs) in patients with symptomatic gallstones is 10 to 20% and less than 5% in asymptomatic individuals. Complications of CBDs are potentially life threatening and include pain, partial

---

**Fig. 3** Approach to small bowel bleed.
or complete biliary obstruction leading to obstructive jaundice, cholangitis, hepatic abscesses, pancreatitis, and rarely secondary biliary cirrhosis. Small CBDs (< 5 mm) pass spontaneously into the duodenum.

The effective treatment for CBDS is therapeutic ERCP. Biliary drainage, preferably endoscopic in settings of acute cholangitis should be elective in mild, within 48 to 72 hours in moderate, and as soon as possible (within 12 hours) in severe cases of acute cholangitis.\(^9\) Failure of biliary drainage is an ominous sign, particularly in severe cases and one may have to resort to percutaneous drainage. For large CBDs, endoscopic papillary balloon dilatation with balloon > 10 mm in diameter is safe and effective technique.\(^4\) The procedure is completed with balloon stone extraction and/or mechanical lithotripsy at a later date. ES with stone extraction is successful in 80 to 90% of cases. In hemodynamically stable patients presenting with cholangitis, balloon and basket catheters are used for CBDS removal. In situations when the CBDs cannot be completely removed, plastic stent is deployed to facilitate adequate biliary drainage. Studies have shown that an indwelling stent may reduce the volume and number of stones possibly by streamlining friction between plastic stent and stones.\(^9\) ES and balloon dilation reduces the need for mechanical lithotripsy by approximately 30 to 50% in comparison with ES alone.\(^9\) For patients above 70 years of age, those with comorbidities like coronary artery disease on anticoagulants and antiplatelets, biliary stenting alone is recommended and endoscopic stone extraction is done when general condition stabilizes. A quarter of patients experience recurrent cholangitis during follow-up. Difficult CBDs are those which are > 1.5 cm in diameter, unusual shape or location (intrahepatic or cystic duct), anatomical factors such as narrow CBD distal to stone, sigmoid shape CBD, stone impaction, shorter length of distal CBD, or acute distal CBD angulation (< 135\(^\circ\)).\(^9\)

**Acute Gallstone Pancreatitis**

The duration of bile duct obstruction is a critical factor contributing to the severity of pancreatitis. Pancreatic necrosis occurs when the duration of obstruction exceeds 48 hours. Magnetic resonance cholangiopancreatography is a useful modality in the diagnosis of biliary obstruction. EUS is an ideal alternative especially for microliths and small CBDs (< 5 mm). In the recent prospective, multicenter, randomized superiority trial in which 232 patients with predicted severe gallstone pancreatitis were assigned to undergo urgent ERCP with biliary sphincterotomy (≤ 24 hours after presentation) or conservative therapy (on-demand ERCP for cholangitis or for persistent cholestasis or retained bile duct stones after recovery from the initial pancreatitis). The primary endpoint was a composite of mortality or major complications (new-onset persistent organ failure, cholangitis, bacteremia, pneumonia, pancreatic insufficiency, or pancreatic parenchymal necrosis) within 6 months. There was no difference in the primary endpoint in patients who underwent urgent ERCP or conservative therapy (38% vs. 44%; \(p = 0.37\)). Urgent ERCP is an ideal, less invasive method to clear the bile duct and is usually indicated in severe gallstone pancreatitis with deranged liver function test and signs of cholangitis, and failure of the patient’s condition to improve within 48 hours despite adequate therapy.\(^9\) There are several guidelines that serve the physicians as a guide toward an emergency ERCP.\(^9\)–\(^10^\)

**Foreign Body Removal**

Foreign body (FB) in the GI tract can be a true FB or a food bolus impaction. FB ingestion accounts for approximately 4% of all urgent endoscopies. True FB ingestion is commonly encountered in pediatric population, whereas food bolus impaction is mostly seen in adults. Most ingested FBs pass spontaneously, 10 to 20% require endoscopic removal (\(\sim\) Fig. 28, C), and less than 1% need surgical intervention.\(^10\) UGIE is performed under conscious sedation and general anesthesia with endotracheal intubation is required in difficult cases to ensure airway protection. Double-channel endoscopes, small-caliber endoscopes, and enteroscopes are required in specific settings. Numerous retrieval devices are available which are wisely chosen depending on FB characteristics. Timing of endoscopic removal is emergent (immediate) for esophageal obstruction due to disk battery and sharp-pointed objects in the esophagus, urgent (within 24 hours) for esophageal objects that are not sharp and pointed, magnets within endoscopic reach, esophageal food impaction without complete obstruction, and objects > 6 cm at or above the duodenum, and nonurgent for coins, objects in the stomach > 2.5 cm in diameter.\(^10\) Special equipment (overtube, hood, transparent distal cap) can be used to protect the airways and the mucosa in case of sharp, pointed, or bulky FBs. When the food bolus is in view, extraction is favored over pushing blindly into the stomach. En bloc or piecemeal extraction, using the most appropriate device available, is the recommended technique.\(^10\) If the pushing technique is attempted, then pressure on the central part of the bolus is the safer way. Pushing is contraindicated due to the risk of perforation and stent migration in cases of food bolus impaction in a stent. FBs larger than 2 to 2.5 cm in diameter or longer than 5 to 6 cm must be extracted before they pass the pylorus as the risk of perforation is high (15–35%). Endoscopic extraction of body packing of drugs is not recommended because the rupture of the package which can lead to fatal overdose and surgery is recommended.\(^10\) Perforation, obstruction, infection, hemorrhage, fistula, and FB migration through the digestive wall can occur in 1 to 5% of cases of which esophageal perforation is the most frequent complication.

**Corrosive Ingestion**

Corrosive ingestion (strong alkalis and acids) at times can be devastating and requires aggressive emergency management which ultimately determines the patient outcome. The determinants of degree of injury include the physical form (solid or liquid), quantity ingested, and whether taken accidentally or with suicidal intent. Massive ingestion of either acids and alkalis causes extensive necrosis of the GI tract.
Endoscopy is the mainstay of management algorithms following caustic ingestion when CT details are not available or there is uncertainty on degree of necrosis. The rationale behind endoscopy is to evaluate the severity of tissue damage, detect perforation, and indicate management plans. While the patient should undergo endoscopy within 24 hours of ingestion, early endoscopy, within < 6 hours following ingestion, may not demonstrate the full picture of injury, and late endoscopy, after 4 days of exposure, increases the risk of perforation.

**Perforations**

Esophagus is a common site for perforation. Spontaneous esophageal perforation (Boerhaave syndrome) accounts for 15% of esophageal perforations and is located along the left border of the lower third of the thoracic esophagus and the size of the defect ranges from 3 to 8 cm. Most perforations are iatrogenic in origin (60%) and occur during a diagnostic or therapeutic endoscopic procedure. Uncommon causes include FBs, caustic injury, postoperative, external injury, and rarely malignancy. An emergency endoscopy is indicated when CT is nonconclusive and diagnosis is uncertain. Endoscopy should be done with caution not to increase the size of perforation and contaminate the surrounding space. Endoscopic treatment is the first line of management for closing esophageal perforation that is identified during the procedure. Use of endoscopic clips, covered metal stents, and endoluminal vacuum therapy have significantly reduced the morbidity and mortality. Endoscopic clip placement is currently the standard method for closing small (< 2 cm) luminal perforations. Endoscopic stents (partially or fully covered SEMS, self-expandable plastic stents) can be used to cover larger defects or complete an unsatisfactory clip closure. While endoscopy remains the definitive procedure, radiological or surgical intervention is required in those with pneumo-/hydrothorax or pleural effusion. Endoluminal vacuum therapy is a promising alternative treatment for esophageal perforation.

**Miscellaneous**

GI tumor-related bleeds account for 12 to 15% of cases of acute GI bleed. Endoscopically, these cases might be difficult to manage because of large, oozing bleeds from fragile vessels caused by neoangiogenesis. Clips are of limited value because the fragility of the tumoral tissue. Thermal therapy including APC, endoloops, and injection therapy have all been tried with limited success rates in achieving initial hemostasis and high rebleeding rates. Hemostatic sprays have been used in the recent times with promising results from few studies. Endoscopic decompression has been utilized in managing patients with volvulus and the recent guidelines recommend nonoperative detorsion with flexible sigmoidoscopy with or without placement of a decompression tube as a first-line therapy in the management of uncomplicated sigmoid volvulus. However, the recurrence rates are as high as 80% after successful endoscopic decompression. For those with perforation, peritonitis, recurrence, or unsuccessful nonoperative decompression, surgical management is warranted. In cases of acute colonic pseudo-obstruction, limited data suggest that colonoscopic decompression might be superior to neostigmine. Colonic stenting is a modality which can be used in acute malignant colonic obstructions as a bridge to surgery or palliative therapy. In a RCT involving 98 patients, colonic stenting was found to have no decisive clinical advantages over emergency surgery in patients with acute left-sided malignant colonic obstruction. However, an updated meta-analysis which included a total of 448 patients found that colonic stenting as a bridge to surgery appears to be a safe approach to malignant large bowel obstruction.

Laparoscopic cholecystectomy is now considered the standard treatment for treatment of acute calculus cholecystitis. In patients unfit for surgery, nonoperative management is typically advised with antibiotic therapy and gallbladder drainage. EUS-guided gallbladder drainage using self-expandable stents is an emerging modality which can be used in this set of patients and found to have similar clinical success rates and adverse events compared with percutaneous drainage.

To summarize, endoscopy and related interventions hold an important place in management of many GI emergencies. Endoscopy has already become an indispensable tool for managing common GI disorders. In the recent years, emergency endotherapy has surpassed many of the earlier more invasive surgeries for complications like massive GI bleed, perforations, etc., and today remains as the mainstay in major GI and hepatobiliary pancreatic complications.

Authors’ Contributions

V.K.D. - data curation, writing-original draft, writing-editing and review; M.K.S. - concept, methodology, data curation, methodology, formal analysis, writing-original draft, writing-editing and review, resources, supervision, administration; V.V. - methodology, investigation, writing-original draft, writing-editing and review; B.V.Y., V.K., M.B.P., and J.V. - data curation, investigation, resources, and writing-editing and review.

Funding

None.

Conflict of Interest

None declared.

References

79 Tagawa T, Yamada M, Minagawa T, et al. Endoscopic characteristics influencing postpolypectomy bleeding in 1147